- The article analyzes diverse Hong Kong stock companies to reveal the underlying business logic of navigating industry cycles through value chain positioning rather than macroeconomic narratives.
- Jiangxi Copper achieved 2026 Q1 revenue of 139 1 billion yuan, up over 25 %, and plans to spin off its copper foil unit and acquire SolGold to move up the value chain.
- Sunshine Pharmaceutical reached 17.7 billion yuan in 2025 revenue and secured global licensing deals, while companies like Maiyue Technology and SciClone Pharmaceuticals leverage digital infrastructure and technological moats.
